Dae Hong Kim

Dae Hong Kim

Auto-generated profile, based on publicly available information

Dae Hong Kim

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2020 in Leukemia
Verified
Journal Article
Open access
PDF file
SAShady Adnan-Awad
Shady Adnan-Awad
DKDaehong Kim
Daehong Kim
HHHelena Hohtari
Helena Hohtari
KJKomal Kumar Javarappa
Komal Kumar Javarappa
TBTania Brandstoetter
Tania Brandstoetter
SMSatu Mustjoki
Satu Mustjoki
The oncogenic protein Bcr-Abl has two major isoforms, p190Bcr-Abland p210Bcr-Abl. While p210Bcr-Ablis the hallmark of chronic myeloid leukemia (CML), p190Bcr-Abloccurs in the majority of Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) patients. In CML, p190Bcr-Abloccurs in a minority of patients associating with distinct hematological features and inferior outcomes, yet the pathogenic role of p190Bcr-Abland potential targeting therapies are largely uncharacterized. We employed next generation sequencing, phospho-proteomic profiling, and drug sensitivity testing to characterize p190Bcr-Ablin CML and hematopoietic progenitor cell line models (Ba/f3 and HPC-LSK). p190Bcr-AblCML patients demonstrated poor response to imatinib and frequent mutations in epigenetic modifiers genes. In contrast with p210Bcr-Abl, p190Bcr-Ablexhibited specific transcriptional upregulation of interferon, interleukin-1 receptor, and P53 signaling pathways, associated with hyperphosphorylation of relevant signaling molecules including JAK1/STAT1 and PAK1 in addition to Src hyperphosphorylation. Comparable to p190Bcr-AblCML patients, p190Bcr-Ablcell lines demonstrated similar transcriptional and phospho-signaling signatures. With the drug sensitivity screening we identified targeted drugs with specific activity in p190Bcr-Ablcell lines including IAP-, PAK1-, and Src inhibitors and glucocorticoids. Our results provide novel insights into the mechanisms underlying the distinct features of p190Bcr-AblCML and promising therapeutic targets for this high-risk patient group.

1 June 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
DKDaehong Kim
Daehong Kim
GPGiljun Park
Giljun Park
JHJani Huuhtanen
Jani Huuhtanen
BGBishwa Ghimire
Bishwa Ghimire
HRHanna Rajala
Hanna Rajala
SMSatu Mustjoki
Satu Mustjoki
Large granular lymphocyte leukemia (LGLL) is characterized by somatic gain-of-function STAT3 mutations. However, the functional effects of STAT3 mutations on primary LGLL cells have not been studied in detail. In this study, we show that CD8+ T cells isolated from STAT3 mutated LGLL patients have high protein levels of epigenetic regulators, such as DNMT1, and are characterized by global hypermethylation. Correspondingly, treatment of healthy CD8+ T cells with IL-6, IL-15, and/or MCP-1 cytokines resulted in STAT3 activation, increased DNMT1, EZH2, c-MYC, l-MYC, MAX, and NFκB levels, increased DNA methylation, and increased oxidative stress. Similar results were discovered in KAI3 NK cells overexpressing gain-of-function STAT3Y640F and STAT3G618R mutants compared to KAI3 NK cells overexpressing STAT3WT. Our results also confirm that STAT3 forms a direct complex with DNMT1, EZH2, and HDAC1. In STAT3 mutated LGLL cells, DNA methyltransferase (DNMT) inhibitor azacitidine abrogated the activation of STAT3 via restored SHP1 expression. In conclusion, STAT3 mutations cause DNA hypermethylation resulting in sensitivity to DNMT inhibitors, which could be considered as a novel treatment option for LGLL patients with resistance to standard treatments.

7 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
DKDaehong Kim
Daehong Kim
GPGiljun Park
Giljun Park
JHJani Huuhtanen
Jani Huuhtanen
SLSofie Lundgren
Sofie Lundgren
RKRajiv K. Khajuria
Rajiv K. Khajuria
SMSatu Mustjoki
Satu Mustjoki
Graft versus host disease (GvHD) is the main complication of allogeneic hematopoietic stem cell transplantation (HSCT). Here we report studies of a patient with chronic GvHD (cGvHD) carrying persistent CD4+ T cell clonal expansion harboring somatic mTOR, NFKB2, and TLR2 mutations. In the screening cohort (n = 134), we detect the mTOR P2229R kinase domain mutation in two additional cGvHD patients, but not in healthy or HSCT patients without cGvHD. Functional analyses of the mTOR mutation indicate a gain-of-function alteration and activation of both mTORC1 and mTORC2 signaling pathways, leading to increased cell proliferation and decreased apoptosis. Single-cell RNA sequencing and real-time impedance measurements support increased cytotoxicity of mutated CD4+ T cells. High throughput drug-sensitivity testing suggests that mutations induce resistance to mTOR inhibitors, but increase sensitivity for HSP90 inhibitors. Our findings imply that somatic mutations may contribute to aberrant T cell proliferations and persistent immune activation in cGvHD, thereby paving the way for targeted therapies.

26 September 2017 in Journal of Peptide Science
Verified
Journal Article
Closed access
PDF file
IYI Na Yoon
I Na Yoon
LLLi Fang Lu
Li Fang Lu
JHJi Hong
Ji Hong
PZPeng Zhang
Peng Zhang
DKDae Hong Kim
Dae Hong Kim
HKHo Kim
Ho Kim

1 February 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
DKDae Hong Kim
Dae Hong Kim
JHJae Sam Hwang
Jae Sam Hwang
ILIk Hwan Lee
Ik Hwan Lee
SNSeung Taek Nam
Seung Taek Nam
JHJi Hong
Ji Hong
HKHo Kim
Ho Kim
The epithelial cells of the gut form a physical barrier against the luminal contents. The collapse of this barrier causes inflammation, and its therapeutic restoration can protect the gut against inflammation. Epidermal growth factor (EGF) enhances mucosal barrier function and increases colonocyte proliferation, thereby ameliorating inflammatory responses in the gut. Based on our previous finding that the insect peptide, CopA3, promotes neuronal growth, we herein tested whether CopA3 could increase the cell proliferation of colonocytes, enhance mucosal barrier function, and ameliorate gut inflammation. Our results revealed that CopA3 significantly increased epithelial cell proliferation in mouse colonic crypts and also enhanced colonic epithelial barrier function. Moreover, CopA3 treatment ameliorated Clostridium difficile toxin A-induced inflammation responses in the mouse small intestine (acute enteritis) and completely blocked inflammatory responses and subsequent lethality in the DSS-induced mouse model of chronic colitis. The marked CopA3-induced increase of colonocyte proliferation was found to require rapid protein degradation of p21Cip1/Waf1, and an in vitro ubiquitination assay revealed that CopA3 directly facilitated ubiquitin ligase activity against p21Cip1/Waf1. Taken together, our findings indicate that the insect peptide, CopA3, prevents gut inflammation by increasing epithelial cell proliferation and mucosal barrier function.

1 June 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
DKDae Hong Kim
Dae Hong Kim
ILIk Hwan Lee
Ik Hwan Lee
SNSeung Taek Nam
Seung Taek Nam
JHJi Hong
Ji Hong
PZPeng Zhang
Peng Zhang
HKHo Kim
Ho Kim